NDAINJECTIONINJECTABLE
Approved
Mar 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER (cefoxitin sodium) by B. Braun is 12. Approved for lower respiratory tract infections, including pneumonia, lung abscess and 33 more indications. First approved in 2006.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Cefoxitin sodium is a second-generation cephalosporin antibiotic supplied in a duplex container with dextrose for intravenous injection. It treats serious infections across respiratory, urinary, intra-abdominal, gynecological, bone/joint, and skin structures by inhibiting bacterial cell wall synthesis. The formulation provides convenient pre-mixed delivery of the antibiotic with glucose carrier.
LOE Approaching
Product is approaching loss of exclusivity with significant generic competition, suggesting declining team headcount and transition focus to cost management and existing customer retention.
Mechanism of Action
12.1 Mechanism of Action Cefoxitin is an antibacterial drug [ ] . 12.2 Pharmacodynamics The pharmacodynamic properties of cefoxitin are unknown. 12.3 Pharmacokinetics Absorption Following an intravenous dose of 1 gram, serum concentrations were 110 mcg/mL at 5 minutes, declining to less than 1…
Worked on CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER at B. Braun? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.